Effect of Immune Checkpoint Inhibitors Plus Chemotherapy on Advanced Gastric Cancer Patients with Elevated Serum AFP or Hepatoid Adenocarcinoma.

Wei LiQian LiYiyi YuYan WangErbao ChenLingli ChenZhiming WangYuehong CuiTian-Shu Liu

Published in: Cancer management and research (2020)

This study suggested PD-1 checkpoint inhibitor plus chemotherapy could benefit AFPGC and HAS patients. Its mechanism of action warrants further investigation.

Keyphrases

locally advanced
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
squamous cell carcinoma
neoadjuvant chemotherapy
dna damage
peritoneal dialysis
patient reported outcomes
cell proliferation
chemotherapy induced